Brendan Stats – CEO – TMK Energy Limited (ASX:TMK) is a gas exploration company listed on the Australian Stock Exchange. TMK holds a 67% interest in the Gurvantes XXXV Project located in the South Gobi Basin of Mongolia and also holds a 20% interest in the Talisman Depp Project containing the Napoleon Structure located in the Barrow-Dampier Sub-basin.
Copyright 2023 – Finance News Network
Source: Finance News Network
29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
Read More24 Feb 2022 - Shaw and Partners Chief Investment Officer Martin Crabb discusses the sectors to invest in given slowing global growth, tightening financial conditions, the risk of inflation and geopolitical imbalances.
Read More29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
Read More19 Aug 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of autoimmune diseases.
Read More19 Mar 2024 - Torque Metals Limited (ASX:TOR) Managing Director Cristian Moreno discusses the roadmap for the company and promising recent results.
Read More15 Jul 2024 - Allan Mason, the former accountant to Kerry Packer during the height of his notoriety, speaks about his best-selling book and tips for cutting back tax costs.
Read More01 Mar 2021 - IVE Group Limited (ASX:IGL) Executive Chairman Geoff Selig talks about the company's strong 1H21 results on the back of a rebound in activity as the adverse impact of COVID disruptions diminishes.
Read More21 Sep 2021 - An introduction to newly appointed BluGlass Limited (ASX:BLG) President, Jim Haden.
Read More31 Mar 2020 - BluGlass Limited (ASX:BLG) Managing Director and CEO,Giles Bourne, talks about the company's 1:1 non-renounceable rights issue, the need to fund its technology through to commercialisation, independent validation of its RPCVD technology and its response to COVID-19.
Read More31 Mar 2020 - Cynata Therapeutics Limited (ASX:CYP) Managing Director, Dr Ross MacDonald, talks 1H20 results, upcoming Phase 2 clinical trials, licensing and strategy to build the company's Cymerus cell therapy platform.
Read More
